Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 11/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 7/20 | 0.81 |
| ▸ | DNMT1 | P26358 | 6/20 | 0.81 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.79 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.72 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.71 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30979358 | 0.92 | DOT1L (0.85) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL14174645 | 0.92 | DOT1L (0.85) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL14191355 | 0.92 | DOT1L (0.85) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL30979354 | 0.90 | DOT1L (0.84) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL5055439 | 0.90 | DOT1L (0.83) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL17309762 | 0.89 | DNMT3B (1.00) | DOT1LDNMT3BDNMT1PRMT1CARM1 | |
| SCHEMBL14174713 | 0.89 | DNMT3B (1.00) | DOT1LDNMT3BDNMT1PRMT1CARM1 | |
| SCHEMBL5055187 | 0.89 | DOT1L (0.80) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL14191440 | 0.88 | DOT1L (1.00) | DOT1LDNMT3BDNMT1PRMT1EZH2 | |
| SCHEMBL9058595 | 0.88 | DOT1L (1.00) | DOT1LDNMT3BDNMT1PRMT1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | DOT1L 24/4885DNMT3B 1/4885DNMT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.